Table 1 Characteristics of included studies

Akitaka Makiyama 2020 [21]

RCT

Japan

44

45

71/18

65(50–89)

67(33–81)

trz + che

che

10

F1; F2;F3; F4; F5

Alexander Stein 2022 [22]

RCT

Germany

44

44

70/18

63(42–80)

60 (41–79)

trz + niv + ipi

che

14.3

F3; F4; F5; F6

Elizabeth C. Smyth 2019 [23]

RCT

UK

22

24

35/11

64(56–69)

64(56–69)

lap + che

che

–

F5

J. Randolph Hecht 2016 [24]

RCT

USA

249

238

365/122

61(19–86)

59(27–84)

lap + che

che

23

F3; F4; F5;

Hofheinz 2022 [30]

RCT

Germany

40

41

64/17

59.5(36–83)

61(24–77)

che + trz/pez

che

22

F1; F3; F5

Josep Tabernero 2018 [25]

RCT

Spain

388

392

617/163

62(54.5–69)

61(54–68)

pez + trz + che

che

25

F3; F4; F5; F6

Bang 2010 [34]

RCT

Korea

294

290

444/140

59.4

58.5

trz + che

che

18.6

F1; F2; F3; F4; F5; F6

Manish A. Shah 2018 [28]

RCT

USA

228

117

–

–

–

trz

che

17.5

F3; F4

Tianshu Liu 2019 [33]

RCT

China

82

81

130/33

59(25–78)

59(23–73)

pez + trz + che

che

22

F1; F3; F4; F5; F6

Merrimack: A study of MM-111 and paclitaxel with trastuzumab in patientsHER2 positive carcinomas of the distal esophagus, gastroesophageal (GE)junction and stomach, unpublished

RCT

USA

42

42

77/7

63.5(31–78)

62.5(35–81)

MM-111 + trz + che

che

–

F4; F5

Taroh Satoh 2019 [32]

RCT

Japan

59

22

67/14

62(23–83)

62.5(33–77)

niv

che

14

F1; F2; F3; F4; F5

Taroh Satoh 2014 [31]

RCT

Japan

132

129

207/54

61(32–79)

62(22–80)

lap + che

che

–

F1; F3; F4; F5;F6

Lin Shen 2013 [35]

RCT

China

36

48

67/17

58.7(48.2–69.2)

58.2(47.7–68.7)

trz + che

che

15.2

F1; F2; F3; F4; F5; F6

K. Shitara 2020 [27]

RCT

Japan

125

62

142/45

65(34–82)

66(28–82)

trx_dex

che

6

F1; F2; F3; F4; F5

Josep Tabernero 2023 [26]

RCT

Spain

388

392

617/163

–

–

pez + trz + che

che

46.1

F1; F2; F3; F4; F5; F6

Thuss-Patience 2017 [29]

RCT

Germany

228

117

272/73

62(19–79)

62(27–80)

trz

che

17.5

F1; F3; F4; F5; F6